{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:00:43Z","timestamp":1787022043968,"version":"build-2736575974"},"reference-count":38,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2019,4,18]],"date-time":"2019-04-18T00:00:00Z","timestamp":1555545600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0215464","type":"journal-article","created":{"date-parts":[[2019,4,18]],"date-time":"2019-04-18T13:41:14Z","timestamp":1555594874000},"page":"e0215464","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":27,"title":["Higher rates of HBsAg clearance with tenofovir-containing therapy in HBV\/HIV co-infection"],"prefix":"10.1371","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3984-883X","authenticated-orcid":true,"given":"Pierre","family":"Gantner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Cotte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clotilde","family":"Allavena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Firouz\u00e9","family":"Bani-Sadr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Huleux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudine","family":"Duvivier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc-Antoine","family":"Valantin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Jacomet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Joly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Ch\u00e9ret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Pugliese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Delobel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Cabi\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Rey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the Dat\u2019AIDS Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2019,4,18]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"e0196057","DOI":"10.1371\/journal.pone.0196057","article-title":"Analysis of risk factors associated with hepatocellular carcinoma in black South Africans: 2000\u20132012","volume":"13","author":"D Mak","year":"2018","journal-title":"PLoS One"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1002\/hep.25800","article-title":"The prevalence of cirrhosis and hepatocellular carcinoma in patients with human immunodeficiency virus infection","volume":"57","author":"GN Ioannou","year":"2013","journal-title":"Hepatology"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1093\/infdis\/163.5.1138","article-title":"The influence of human immunodeficiency virus type 1 infection on the development of the hepatitis B virus carrier state","volume":"163","author":"NJ Bodsworth","year":"1991","journal-title":"J Infect Dis"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1097\/QAD.0000000000001574","article-title":"HIV-hepatitis B virus coinfection: epidemiology, pathogenesis, and treatment","volume":"31","author":"KP Singh","year":"2017","journal-title":"AIDS"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1097\/QAD.0000000000000222","article-title":"Causes of death among HIV-infected patients in France in 2010 (national survey): trends since 2000","volume":"28","author":"P Morlat","year":"2014","journal-title":"AIDS"},{"key":"ref6","first-page":"1","article-title":"Hepatitis B virus in drug users in France: prevalence and vaccination history, ANRS-Coquelicot Survey 2011\u20132013","volume":"2017","author":"C Brouard","journal-title":"Epidemiol Infect"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"9","DOI":"10.7326\/M16-0240","article-title":"Chronic Hepatitis B and C Virus Infection and Risk for Non-Hodgkin Lymphoma in HIV-Infected Patients: A Cohort Study","volume":"166","author":"Q Wang","year":"2017","journal-title":"Ann Intern Med"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1017\/S0950268817001947","article-title":"Current prevalence of chronic hepatitis B and C virus infection in the general population, blood donors and pregnant women in the EU\/EEA: a systematic review","volume":"145","author":"SHI Hofstraat","year":"2017","journal-title":"Epidemiol Infect"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1186\/s12879-017-2568-5","article-title":"Prevalence of hepatitis B and delta according to HIV-type: a multi-country cross-sectional survey in West Africa","volume":"17","author":"PA Coffie","year":"2017","journal-title":"BMC Infect Dis"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"e0150512","DOI":"10.1371\/journal.pone.0150512","article-title":"Hepatitis B and C Co-Infection in HIV Patients from the TREAT Asia HIV Observational Database: Analysis of Risk Factors and Survival","volume":"11","author":"M Chen","year":"2016","journal-title":"PLoS One"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","year":"2017","journal-title":"J Hepatol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"NA Terrault","year":"2018","journal-title":"Hepatology"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1590\/s1518-8787.2017051006693","article-title":"Evolution of hepatitis B serological markers in HIV coinfected patients: a case study","volume":"51","author":"AL Toscano","year":"2017","journal-title":"Rev Saude Publica"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jcv.2017.08.008","article-title":"Development of anti-hepatitis B surface (HBs) antibodies after HBs antigen loss in HIV-hepatitis B virus co-infected patients","volume":"95","author":"A Boyd","year":"2017","journal-title":"J Clin Virol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/QAD.0b013e328340fde2","article-title":"Clinical and virological outcomes in HIV-infected patients with chronic hepatitis B on long-term nucleos(t)ide analogues","volume":"25","author":"L Mart\u00edn-Carbonero","year":"2011","journal-title":"AIDS"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1002\/hep.27604","article-title":"Hepatitis B surface antigen genetic elements critical for immune escape correlate with hepatitis B virus reactivation upon immunosuppression","volume":"61","author":"R Salpini","year":"2015","journal-title":"Hepatology"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1053\/j.gastro.2004.03.018","article-title":"Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy","volume":"126","author":"B Werle-Lapostolle","year":"2004","journal-title":"Gastroenterology"},{"key":"ref18","article-title":"Uptake of tenofovir-based antiretroviral therapy among HIV-HBV-coinfected patients in the EuroSIDA study","author":"L Peters","year":"2018","journal-title":"Antivir Ther"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/j.1468-1293.2009.00719.x","article-title":"A large French prospective cohort of HIV-infected patients: the Nadis Cohort","volume":"10","author":"P Pugliese","year":"2009","journal-title":"HIV Med"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1002\/jmv.24064","article-title":"Correlation between the promoter basal core and precore mutations and HBsAg quantification in French blood donors infected with hepatitis B virus","volume":"87","author":"A Pivert","year":"2015","journal-title":"J Med Virol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1093\/infdis\/jis439","article-title":"Hepatitis B surface antigen declines and clearance during long-term tenofovir therapy in patients coinfected with HBV and HIV","volume":"206","author":"R Zoutendijk","year":"2012","journal-title":"J Infect Dis"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1080\/13854046.2017.1306111","article-title":"Review of doing Bayesian data analysis: a tutorial with R, JAGS, and Stan (second edition)","volume":"31","author":"CE Gaudet","year":"2017","journal-title":"Clin Neuropsychol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1111\/liv.13432","article-title":"Hepatitis B s antigen kinetics during treatment with nucleos(t)ides analogues in patients with hepatitis B e antigen-negative chronic hepatitis B","volume":"37","author":"A Striki","year":"2017","journal-title":"Liver Int"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"917","DOI":"10.3851\/IMP1645","article-title":"Efficacy of tenofovir disoproxil fumarate\/emtricitabine compared with emtricitabine alone in antiretroviral-naive HIV-HBV coinfection in Thailand","volume":"15","author":"A Avihingsanon","year":"2010","journal-title":"Antivir Ther"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1177\/135965350801300315","article-title":"Evidence of long-term suppression of hepatitis B virus DNA by tenofovir as rescue treatment in patients coinfected by HIV","volume":"13","author":"E Quiros-Roldan","year":"2008","journal-title":"Antivir Ther"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.coviro.2018.04.006","article-title":"Perspectives and limitations for nucleo(t)side analogs in future HBV therapies","volume":"30","author":"M Levrero","year":"2018","journal-title":"Curr Opin Virol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1007\/s10620-015-3960-x","article-title":"Effectiveness and Safety of Tenofovir Disoproxil Fumarate in Chronic Hepatitis B: A 3-Year Prospective Field Practice Study in Germany","volume":"61","author":"J Petersen","year":"2016","journal-title":"Dig Dis Sci"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1177\/2325957415586258","article-title":"Outcomes in HIV\/HBV-Coinfected Patients in the Tenofovir Era Are Greatly Affected by Immune Suppression","volume":"14","author":"AJ Huang","year":"2015","journal-title":"J Int Assoc Provid AIDS Care"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1080\/17474124.2017.1386554","article-title":"Tenofovir alafenamide as compared to tenofovir disoproxil fumarate in the management of chronic hepatitis B with recent trends in patient demographics","volume":"11","author":"YC Hsu","year":"2017","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1080\/14787210.2018.1428561","article-title":"Tenofovir alafenamide (TAF) treatment of HBV, what are the unanswered questions?","volume":"16","author":"M Vigan\u00f2","year":"2018","journal-title":"Expert Rev Anti Infect Ther"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1002\/hep.21612","article-title":"HBsAg seroclearance in asymptomatic carriers of high endemic areas: appreciably high rates during a long-term follow-up","volume":"45","author":"CM Chu","year":"2007","journal-title":"Hepatology"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3851\/IMP1621","article-title":"The natural history of chronic HBV infection and geographical differences","volume":"15","author":"YF Liaw","year":"2010","journal-title":"Antivir Ther"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"e25054","DOI":"10.1002\/jia2.25054","article-title":"Research gaps in viral hepatitis","volume":"21","author":"A Boyd","year":"2018","journal-title":"J Int AIDS Soc"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1089\/vim.2012.0036","article-title":"Improved immune status corresponds with long-term decline of quantitative serum hepatitis B surface antigen in HBV\/HIV co-infected patients","volume":"25","author":"E Arendt","year":"2012","journal-title":"Viral Immunol"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1111\/apt.14636","article-title":"Impact of HBV genotype and mutations on HBV DNA and qHBsAg levels in patients with HBeAg-negative chronic HBV infection","volume":"47","author":"L Kuhnhenn","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"e43143","DOI":"10.1371\/journal.pone.0043143","article-title":"Hepatitis B surface antigen concentrations in patients with HIV\/HBV co-infection","volume":"7","author":"J Jaroszewicz","year":"2012","journal-title":"PLoS One"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1111\/jgh.13156","article-title":"Hepatitis B surface antigen quantification as a predictor of seroclearance during treatment in HIV-hepatitis B virus coinfected patients from Sub-Saharan Africa","volume":"31","author":"A Boyd","year":"2016","journal-title":"J Gastroenterol Hepatol"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/liv.12403","article-title":"HBsAg quantification: useful for monitoring natural history and treatment outcome","volume":"34","author":"M Martinot-Peignoux","year":"2014","journal-title":"Liver Int"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0215464","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,16]],"date-time":"2022-09-16T04:53:10Z","timestamp":1663303990000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0215464"}},"subtitle":[],"editor":[{"given":"Jee-Fu","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2019,4,18]]},"references-count":38,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2019,4,18]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0215464","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,18]]}}}